Last reviewed · How we verify
placebo for risankizumab
placebo for risankizumab is a Small molecule drug developed by AbbVie. It is currently FDA-approved.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
At a glance
| Generic name | placebo for risankizumab |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (risankizumab in this case) by comparison. Any observed effects in placebo recipients are attributed to the placebo effect, natural disease progression, or regression to the mean rather than direct pharmacological action.
Approved indications
Common side effects
- Adverse events in placebo groups typically reflect natural disease progression or non-specific effects
Key clinical trials
- Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis (PHASE4)
- A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis (PHASE3)
- Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease (PHASE3)
- A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. (PHASE3)
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (PHASE3)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (PHASE3)
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo for risankizumab CI brief — competitive landscape report
- placebo for risankizumab updates RSS · CI watch RSS
- AbbVie portfolio CI
Frequently asked questions about placebo for risankizumab
What is placebo for risankizumab?
How does placebo for risankizumab work?
Who makes placebo for risankizumab?
What development phase is placebo for risankizumab in?
What are the side effects of placebo for risankizumab?
Related
- Manufacturer: AbbVie — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing